Limits...
Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations.

Lopez A, Mateos MV, Oriol A, Valero M, Martínez J, Lorenzo JI, Perez M, Martinez R, de Paz R, Granell M, De Arriba F, Blanchard MJ, Peñalver FJ, Bello JL, Martin ML, Bargay J, Blade J, Lahuerta JJ, San Miguel JF, de la Rubia J - Leuk Res Rep (2015)

Bottom Line: We report the characteristics of relapse, treatment response, and outcomes of 145 elderly patients with multiple myeloma in first relapse after front-line treatment with VMP or VTP.Reappearance of CRAB symptoms (113 patients) and more aggressive forms of disease (32 patients) were the most common patterns of relapse.Overall survival was longer among patients receiving VMP as front-line induction (21.4 vs. 14.4 months, P=0.037), in patients achieving CR (28.3 vs. 14.8 months; P=0.04), and in patients without aggressive relapse (28.6 vs. 7.6 months; P=0.0007).

View Article: PubMed Central - PubMed

Affiliation: Hematology, Hospital Arnau de Vilanova, Valencia, Spain.

ABSTRACT
We report the characteristics of relapse, treatment response, and outcomes of 145 elderly patients with multiple myeloma in first relapse after front-line treatment with VMP or VTP. Reappearance of CRAB symptoms (113 patients) and more aggressive forms of disease (32 patients) were the most common patterns of relapse. After second-line therapy, 75 (51.7%) patients achieved at partial response and 16 (11%) complete response (CR). Overall survival was longer among patients receiving VMP as front-line induction (21.4 vs. 14.4 months, P=0.037), in patients achieving CR (28.3 vs. 14.8 months; P=0.04), and in patients without aggressive relapse (28.6 vs. 7.6 months; P=0.0007).

No MeSH data available.


Related in: MedlinePlus

Overall survival according to the type of response achieved after relapse.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4588395&req=5

f0020: Overall survival according to the type of response achieved after relapse.

Mentions: At the time of analysis, 108 (74.4%) patients have died, including 44 (65.6%) and 64 (82%) in the VMP and VTP arms, respectively. Median OS from start of subsequent therapy in the overall series of patients was 17 months (95% IC: 13.8–22.4). OS from time of relapse was significantly longer among patients receiving front-line therapy with VMP, 21.4 (95% IC: 13.8–36.4) months when compared with those in the VTP group, 14.4 (95% IC: 11.9–21.7) months (P= 0.037; Fig. 3). Likewise, OS was also significantly longer among patients achieving CR after relapse when compared with patients who did not achieve CR (28.3 vs. 14.8 months; P=0.04) (Fig. 4).


Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations.

Lopez A, Mateos MV, Oriol A, Valero M, Martínez J, Lorenzo JI, Perez M, Martinez R, de Paz R, Granell M, De Arriba F, Blanchard MJ, Peñalver FJ, Bello JL, Martin ML, Bargay J, Blade J, Lahuerta JJ, San Miguel JF, de la Rubia J - Leuk Res Rep (2015)

Overall survival according to the type of response achieved after relapse.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4588395&req=5

f0020: Overall survival according to the type of response achieved after relapse.
Mentions: At the time of analysis, 108 (74.4%) patients have died, including 44 (65.6%) and 64 (82%) in the VMP and VTP arms, respectively. Median OS from start of subsequent therapy in the overall series of patients was 17 months (95% IC: 13.8–22.4). OS from time of relapse was significantly longer among patients receiving front-line therapy with VMP, 21.4 (95% IC: 13.8–36.4) months when compared with those in the VTP group, 14.4 (95% IC: 11.9–21.7) months (P= 0.037; Fig. 3). Likewise, OS was also significantly longer among patients achieving CR after relapse when compared with patients who did not achieve CR (28.3 vs. 14.8 months; P=0.04) (Fig. 4).

Bottom Line: We report the characteristics of relapse, treatment response, and outcomes of 145 elderly patients with multiple myeloma in first relapse after front-line treatment with VMP or VTP.Reappearance of CRAB symptoms (113 patients) and more aggressive forms of disease (32 patients) were the most common patterns of relapse.Overall survival was longer among patients receiving VMP as front-line induction (21.4 vs. 14.4 months, P=0.037), in patients achieving CR (28.3 vs. 14.8 months; P=0.04), and in patients without aggressive relapse (28.6 vs. 7.6 months; P=0.0007).

View Article: PubMed Central - PubMed

Affiliation: Hematology, Hospital Arnau de Vilanova, Valencia, Spain.

ABSTRACT
We report the characteristics of relapse, treatment response, and outcomes of 145 elderly patients with multiple myeloma in first relapse after front-line treatment with VMP or VTP. Reappearance of CRAB symptoms (113 patients) and more aggressive forms of disease (32 patients) were the most common patterns of relapse. After second-line therapy, 75 (51.7%) patients achieved at partial response and 16 (11%) complete response (CR). Overall survival was longer among patients receiving VMP as front-line induction (21.4 vs. 14.4 months, P=0.037), in patients achieving CR (28.3 vs. 14.8 months; P=0.04), and in patients without aggressive relapse (28.6 vs. 7.6 months; P=0.0007).

No MeSH data available.


Related in: MedlinePlus